Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 690469101 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Takeda Pharmaceutical Co Ltd
13G/A
|
12.3% |
12/9/2025
Event 12/8/2025
|
||
| Takeda Pharmaceutical Company Limited | 12.3% | |||
| Takeda Pharmaceutical U.S.A., Inc. | 9.8% | |||
| Janus Henderson Group PLC 13G | 10.0% |
12/8/2025
Event 11/28/2025
|
||
|
RA Capital Management, L.P.
13G/A
|
9.9% |
8/14/2026
Event 6/30/2026
|
||
| RA Capital Management, L.P. | 9.9% | |||
| Peter Kolchinsky | 9.9% | |||
| Rajeev Shah | 9.9% | |||
| RA Capital Healthcare Fund, L.P. | 9.9% | |||
|
Sirenia Capital Management LP
13G
|
9.9% |
5/15/2026
Event 3/31/2026
|
||
| Sirenia Capital Management LP | 9.9% | |||
| Alex Silverstein | 9.9% | |||
|
Affinity Asset Advisors, LLC
13G/A
|
7.9% |
8/13/2026
Event 6/30/2026
|
||
| Affinity Asset Advisors, LLC | 7.9% | |||
| Michael Cho | 7.9% | |||
|
Eventide Asset Management, LLC
13G/A
|
6.3% |
8/14/2026
Event 6/30/2026
|
||
| Eventide Asset Management, LLC | 6.3% | |||
| Finny Kuruvilla, M.D., Ph. D. | 6.3% | |||
| Robin C. John | 6.3% | |||
| BlackRock, Inc. 13G | 5.8% |
7/29/2026
Event 6/30/2026
|
||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (8) | ||||
|
ADAR1 Capital Management, LLC
13G/A
|
5.1%
Checked 5% or less
|
8/14/2026
Event 6/30/2026
|
||
| ADAR1 Capital Management, LLC | 5.1% | |||
| ADAR1 Capital Management GP, LLC | 4.9% | |||
| Daniel Schneeberger | 5.1% | |||
|
Balyasny Asset Management L.P.
13G/A
|
4.99% |
8/14/2026
Event 6/30/2026
|
||
| Balyasny Asset Management L.P. | 4.99% | |||
| Bam GP LLC | 4.99% | |||
| Balyasny Asset Management Holdings LP | 4.99% | |||
| Dames GP LLC | 4.99% | |||
| Dmitry Balyasny | 4.99% | |||
| Jeremy M. Levin 13G/A | 4.5% |
5/14/2026
Event 3/31/2026
|
||
|
Federated Hermes, Inc.
13G/A
|
4.2% |
7/8/2026
Event 6/30/2026
|
||
| Federated Hermes, Inc. | 4.2% | |||
| Voting Shares Irrevocable Trust | 4.2% | |||
| Thomas R. Donahue | 4.2% | |||
| Ann C. Donahue | 4.2% | |||
| J. Christopher Donahue | 4.2% | |||
|
Madison Avenue Partners, LP
13G/A
|
4.0% |
2/14/2025
Event 12/31/2024
|
||
| Madison Avenue Partners, LP | 4.0% | |||
| Madison Avenue International LP | 4.0% | |||
| EMAI Management, LLC | 4.0% | |||
| Madison Avenue GP, LLC | 4.0% | |||
| Caraway Jackson Investments LLC | 4.0% | |||
| Eli Samaha | 4.0% | |||
|
Point72 Asset Management, L.P.
13G/A
|
1.3% |
5/15/2026
Event 3/31/2026
|
||
| Point72 Asset Management, L.P. | 1.3% | |||
| Point72 Capital Advisors, Inc. | 1.3% | |||
| Steven A. Cohen | 1.3% | |||
|
Rubric Capital Management LP
13G/A
|
0.7% |
7/9/2025
Event 6/30/2025
|
||
| Rubric Capital Management LP | 0.7% | |||
| David Rosen | 0.7% | |||
|
Biotechnology Value Fund L P
13G/A
|
0% |
7/21/2025
Event 7/17/2025
|
||
| Biotechnology Value Fund L P | 0% | |||
| BVF I GP LLC | 0% | |||
| Biotechnology Value Fund II LP | 0% | |||
| BVF II GP LLC | 0% | |||
| Biotechnology Value Trading Fund OS LP | 0% | |||
| BVF Partners OS Ltd. | 0% | |||
| BVF GP Holdings LLC | 0% | |||
| BVF Partners L P/IL | 0% | |||
| BVF Inc/IL | 0% | |||
| Lampert Mark N | 0% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 1 | 1.38 k | $3.44 k |
| 2026 Q2 | 136 | 147 M | $398 M |
| 2026 Q1 | 109 | 105 M | $233 M |
| 2025 Q4 | 89 | 61.8 M | $101 M |
| 2025 Q3 | 86 | 36.2 M | $47.1 M |
| 2025 Q2 | 74 | 36.0 M | $11.9 M |
| 2025 Q1 | 85 | 46.4 M | $14.5 M |
| 2024 Q4 | 85 | 47.6 M | $44.4 M |
| 2024 Q3 | 79 | 47.8 M | $56.4 M |
| 2024 Q2 | 80 | 47.6 M | $36.6 M |
| 2024 Q1 | 88 | 52.0 M | $159 M |
| 2023 Q4 | 82 | 53.5 M | $172 M |
| 2023 Q3 | 65 | 42.3 M | $163 M |
| 2023 Q2 | 72 | 41.0 M | $135 M |
| 2023 Q1 | 64 | 38.7 M | $99.8 M |
| 2022 Q4 | 63 | 38.8 M | $72.1 M |
| 2022 Q3 | 61 | 35.6 M | $65.5 M |
| 2022 Q2 | 58 | 34.6 M | $74.5 M |
| 2022 Q1 | 65 | 35.1 M | $110 M |
| 2021 Q4 | 72 | 34.3 M | $110 M |
| 2021 Q3 | 77 | 33.6 M | $113 M |
| 2021 Q2 | 87 | 33.4 M | $131 M |
| 2021 Q1 | 96 | 36.3 M | $146 M |
| 2020 Q4 | 95 | 27.8 M | $64.9 M |
| 2020 Q3 | 100 | 25.1 M | $144 M |
| 2020 Q2 | 88 | 22.6 M | $166 M |
| 2020 Q1 | 62 | 16.7 M | $49.7 M |
| 2019 Q4 | 66 | 18.9 M | $78.5 M |
| 2019 Q3 | 40 | 8.21 M | $26.6 M |
| 2019 Q2 | 37 | 10.1 M | $18.7 M |
| 2019 Q1 | 51 | 12.3 M | $21.7 M |
| 2018 Q4 | 49 | 6.93 M | $16.8 M |
| 2018 Q3 | 53 | 7.68 M | $43.5 M |
| 2018 Q2 | 49 | 7.95 M | $62.0 M |
| 2018 Q1 | 49 | 7.34 M | $51.9 M |
| 2017 Q4 | 49 | 7.82 M | $77.2 M |
| 2017 Q3 | 42 | 7.22 M | $61.5 M |
| 2017 Q2 | 46 | 7.99 M | $81.8 M |